H.C. Wainwright analyst Kevin Dede maintained a Buy rating on Medical Transcription Billing (NASDAQ: MTBC) today and set a price target of $5. The company’s shares closed yesterday at $3.32.
According to TipRanks.com, Dede has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.5% and a 34.6% success rate. Dede covers the Consumer Goods sector, focusing on stocks such as Top Image Systems, Microvision, and SuperCom.
Medical Transcription Billing has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
Based on Medical Transcription Billing’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $75.04K. In comparison, last year the company had a GAAP net loss of $2.71 million.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Medical Transcription Billing Corp. is a healthcare information technology company, which engages in the provision of integrated suite of proprietary web-based solutions. Its products and services include electronic health records, practice management, patient engagement, medical billing, value added, consultancy, medical transcription, and business intelligence. The company was founded by Mahmud Ul Haq on September 28, 2001 and is headquartered in Somerset, NY.
